BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Artificial Intelligence

[White paper] High Throughput Quantum Chemistry for Drug Discovery - Towards Reaction Screening

by Peter Jarowski  (contributor )   •   Feb. 15, 2018  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

In the domain of drug discovery, there can be a world of difference between a computer-generated hit compound, which is predicted to bind well to a drug target and what can be reliably synthesized at scale, or indeed synthesized at all. This discrepancy has been a lingering point of discord between the Discovery and R&D efforts in the chemical industry. Computer-aided drug design (CADD) has become an increasingly valuable tool by providing essential screening data and unique insight into drug action and mechanism, but it does not model the more complex world of chemical reactivity and synthetic chemistry.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Synthetic chemistry and computational chemistry traditionally overlap at the interface of physical organic chemistry (kinetics and mechanistic rational) and reaction design (often catalysis) where quantum mechanics is leveraged to provide quantitative predictions. There is a growing need for more quantum computations of reactions to control for this ‘obtainability’ factor extending to the optimization process as well, not just for R&D scale reactions but all the way through to production. Synthetic and process chemistry efforts carried out by medicinal chemists and chemical engineers carry an increasingly greater risk and cost to execute but suffer from not having their own computational CADD-like counterpart to achieve the same benefits that modeling is known to deliver at the beginning of the process.

In principle, theorists can now actually inform synthetic chemists how to synthesize that ‘impossible’ molecule, but this has come at a considerable cost in time and computing resources. Thus, in practice, the vast majority of computational work is performed on molecular structure and docking using molecular mechanics running on personal computers. This means that the interface between what could be a great drug and what lead compounds can actually be made is left with a technological gap where the analysis of the reaction transformations necessary to achieve these lead structures are left largely to literature searching or more high throughput data-driven methods like cheminformatics, and more recently, machine learning approaches.

 

State of Computation in Industry

Following increasing trends in digitization and computation, the chemical industry is preparing for an increasingly large user-base of chemical researchers and practitioners engaging with computations. There are over 1 million potential individual users working across thousands of innovation-driven companies. Roughly USD 19 billion p.a. will be spent on computation by 2020 within chemical R&D compared to about USD 9.5 billion currently.

As computation becomes more ubiquitous it will become an expected aspect of chemical workflow. This technology is becoming more central to the process of drug design as it provides metrics at the point in in the development and research cycle when ideas are transformed into real-world lead compounds.

Computation is still a niche market. The software sales market for traditional software packages in chemistry is This market is dominated by a number of high-end suites of programs. Accelrys and Schroedinger Inc. represent a large market share for general computational chemistry environments. In 2013, Accelrys had a revenue ca. 170 M USD, a growth of 3.7% and employed over 750 people with over 2000 clients. In 2008, Accelys was valued at 100 M USD. The company was later sold to Dassault Systems under the new label Biovia for 750 M USD in 2012. The market is clearly growing (5% per year). The purchase price for industrial agents for these software range from USD 2k - 50k. In the quantum area, Schroedinger is the most innovative and is recently moving into the cloud area with early elements of automation as well.

Continue reading

This content available exclusively for BPT Mebmers

 BPT Membership 

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read:

21 Life Science Marketplaces to Try in 2024
by Andrii Buvailo
The Increasing Role of CROs in the Pharmaceutical Industry
by Andrii Buvailo
36 Web Resources For Target Hunting In Drug Discovery
by Alfred Ajami, Andrii Buvailo
How To Hunt For Drugs In Dark Chemical Matter
by Alfred Ajami
Converging Trends Brings Organic Electrochemistry To The Front Line Of Drug Discovery
by Alfred Ajami
8 Biopharma Trends and Top Startups to Follow in 2017
by Andrii Buvailo

 

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.